Skip to main content
Journal of Microbiology and Biotechnology logoLink to Journal of Microbiology and Biotechnology
. 2023 Jan 6;33(5):574–581. doi: 10.4014/jmb.2209.09034

The Clinical Characteristic and Management of Patients with Nocardiosis in a Tertiary Hospital in China

Peilin Liu 1,2, Zhiqian Wang 1, Zijuan Jian 1, Xuan Liu 1, Yanming Li 1, Qun Yan 1, Baiyun Zhong 1, Mengting Liao 1, Xianghui Liang 1,*, Wenen Liu 1,2,*
PMCID: PMC10236171  PMID: 36823137

Abstract

Nocardiosis is an uncommon opportunistic bacterial infection which becomes a significant health problem due to its increasing incidence and high mortality rate. However, many nocardiosis patients are underdiagnosed by physicians. To summarize the clinical characteristics and management of nocardiosis would help with better diagnosis and prognosis of nocardiosis. This retrospective study was conducted based on the medical records of nocardiosis patients between January 2015 and December 2021 in a tertiary hospital in China. Overall, 44 nocardiosis patients with 54 specimens were included. The patients consisted of 26 males and 18 females with a mean age of 50.4 ± 13.2 years. Among 44 patients, 26 (59.1%) were previously given immunosuppressive therapy. Connective tissue diseases (CTDs) were the most common underlying disease (16/44). The most frequent infection sites were the lungs (17/44) and skin or soft tissues (8/44). Common symptoms included cough (23/44), expectoration (18/44), fever (15/44), and subcutaneous abscesses (15/44). Forty-five out of 54 specimens (83.3%) required over 48 hours of culture time for nocardiosis detection. Thirty-six patients were cured or improved, 5 patients were discharged from the hospital due to poor prognosis, and 1 patient died. The average diagnosis time of poor prognosis cases was 19.7 days, which was significantly longer than those of improved or cured patients (7.3 days). Immunosuppressed patients comprise a large part of nocardiosis cases, which is worth attention in clinical practice. Early diagnosis, specifically through prolonged cultivation time of specimen, could help achieve better prognosis of nocardiosis patients.

Keywords: Nocardia, Nocardiosis, clinical characteristic, immunosuppressed patients, early diagnosis

Introduction

Nocardia is a genus Gram-positive bacterium that belongs to aerobic actinomycetes [1]. It is pervasive in soil, fresh air, saltwater, and dust [2]. Nocardia was first discovered in 1888 by veterinarian Edmond Nocard [3, 4]. Advances in molecular techniques, such as 16S rRNA gene sequencing and matrix-assisted laser desorption ionization time-of-flight spectrometry have helped to identify over 100 species of Nocardia [1, 4, 5]. Approximately one-third of Nocardia species have been recognized as human pathogens [6, 7].

Nocardiosis most frequently involves the lungs, central nervous system (CNS), and skin and can also affect the joints, kidneys, and other organs [8, 9]. Several studies have revealed that immunocompromised patients and recipients of solid organ transplants were more susceptible to nocardiosis, especially the disseminated nocardiosis [10-12].

In recent years, the incidence of nocardiosis has increased significantly, which may be associated with an increasing number of immunocompromised patients and advancements in laboratory detection methods, along with more attention from clinicians due to its high mortality rate ranging from 20% to 30% [13-15]. However, Nocardia is easily missed, delayed or misdiagnosed in the clinic, resulting in inappropriate empirical therapy and poor outcomes of patients. Because Nocardia is an infrequent and difficult-to-culture bacteria and the isolation and identification of it usually takes days to weeks from the clinical specimen [13]. Moreover, there are no specific clinical signs and symptoms for the diagnosis of nocardiosis [16]. Consequently, the diagnosis of nocardiosis requires high level of suspicious and experience of clinicians and microbiology laboratory. To develop the diagnosis, treatment and prognosis of nocardiosis, a comprehensive and detailed knowledge of Nocardia identification and the clinical characteristics of nocardiosis is urgently required. Most of the existing literatures on nocardiosis consist of case reports or small case series, and there have been few systematic analyses of nocardiosis. Marked geographical variability in Nocardia distribution has also been investigated, but in China, such research remains rare [17]. Here, we retrospectively summarized the clinical characteristics and management of nocardiosis, including demographic data, underlying diseases, clinical manifestations, radiological examinations, diagnosis, treatment and outcomes that occurred in the past seven years in a tertiary hospital in China. Our finding will provide a better understanding of nocardiosis and contribute experience for the early clinical diagnosis and treatment, improving the prognosis of patients.

Materials and Methods

Clinical Data Collection

Data on nocardiosis cases were collected from patients in a tertiary hospital in China from January 2015 to December 2021. Patients with nocardiosis were identified from the records of the clinical microbiology laboratory. Demographic data (including sex, age, and visit time), underlying diseases [connective tissue disease (CTD), hypertension, respiratory disease, and history of immunosuppressive therapy], clinical manifestations (fever, cough, expectoration, subcutaneous abscesses, shortness of breath, muscle soreness, asthenia, altered consciousness, and hemoptysis), laboratory tests [routine blood tests, hepatic and renal function, erythrocyte sedimentation rate, serum C-reactive protein (CRP), and procalcitonin (PCT)], radiological examinations [chest computed tomography (CT) and magnetic resonance imaging], diagnosis, treatment (antimicrobial and surgical management), and outcomes were retrospectively reviewed.

Isolation and Identification of Nocardia

In this study, all Nocardia strains were isolated from clinical specimens. Different sample types were collected, including sputum, bronchial secretions, bronchoalveolar lavage, skin abscesses, abscess puncture fluid, wound secretion/pus, blood, cerebrospinal fluid (CSF), brain abscess drainage, ocular secretion, peritoneal effusion, joint fluid, and tissue blocks.

The clinical specimens were prepared for smear microscopic examination, incubated, and cultured on different agar plates simultaneously. For blood samples, it would inject into aerobic, anaerobic, or paediatric blood culture bottles and incubated in an automated blood culture monitoring system. routine culture plates were blood agar, HM/MAC agar, chocolate agar, MacConkey agar and anaerobic blood agar. If Gram-staining and modified acid-fast staining were positive and filamentous and a branched suspicious bacterium was found, microbiologists considered prolonging the conventional culture time (>2 days). Nocardia isolates were identified via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) using a MALDI Biotyper (Bruker Daltonics). A MALDI-TOF MS scores between 1.7 to 2.0 represented genus-level identification, while a score of higher or equal to 2.0 represented identification at species level. Anything less than 1.7 indicated unreliable identification. The specific microbiological examination procedures for the common specimens are shown in Fig. 1.

Fig. 1. The specific microbiology examinations of common specimen.

Fig. 1

All Nocardia strains were isolated from different clinical specimens. The clinical specimens were prepared for smear microscopic examination, incubated, and cultured on different agar plates simultaneously. Nocardia isolates were identified using matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry finally.

Case Definition

A diagnosis of nocardiosis required at least one positive culture result for each sample, and all patients included in the analysis had complete information. Disseminated nocardiosis was defined as when two or more non-contiguous organs are clearly infected with Nocardia [18, 19].

Statistical Analysis

Categorical variables were expressed as numbers and percentages. Continuous variables were presented as means ± standard deviation.

Results

Demographic Characteristic of Nocardiosis Cases

Forty-four patients (26 men, 18 women) with nocardiosis between January 2015 and December 2021 were included in this study. The mean age was 50.4 ± 13.2 years, ranging from 5 to 75 years old. Only one patient was younger than 20 years, and the majority (72.7%) were older than 45 years (Table 1).

Table 1.

The demographic and clinical characteristics of patients with nocardiosis cases.

Variables Nocardiosis cases (n = 44)
Age(years), mean ± SD (range) 50.4 ± 13.2
Sex
Male 26 (59.1%)
Female 18 (40.9%)
Underlying diseases 33 (75.0%)
CTD 16 (36.3%)
Chronic kidney disease 10 (22.7%)
Hypertension 9 (20.5%)
Diabetes 7 (15.9%)
Respiratory disease 5 (11.4%)
Viral hepatitis B 5 (11.4%)
CHD 3 (6.8%)
Leukemia 2 (4.5%)
Glucocorticoid or immunosuppressive therapy 26 (59.1%)
Infection sites
Lung 17 (38.6%)
Skin and soft tissue 8 (18.2%)
CNS 6 (13.6%)
Bloodstream 6 (13.6%)
Lung, skin and soft tissue 4 (9.1%)
Lung and intraperitoneal 2 (4.5%)
Eye 1 (2.3%)
Clinical characteristics 44 (100%)
Cough 23 (52.3%)
Expectoration 18 (40.9%)
Fever 15 (34.1%)
Subcutaneous abscesses 15 (34.1%)
Shortness of breath 10 (22.7%)
Headache 7 (15.9%)
Muscle soreness 6 (13.6%)
Asthenia 6 (13.6%)
Altered consciousness 4 (10.3%)
Hemoptysis 4 (10.3%)
Chest pain 4 (10.3%)
Laboratory tests
Elevated white cells 26 (59.1%)
Elevated neutrophil proportion 30(68.2%)
Decreased lymphocyte counts 34 (77.3%)
Decreased hemoglobin levels 20 (45.5%)
Elevated platelet levels 7 (15.9%)
Decreased serum album levels 32 (72.7%)
Elevated ECR 28 (63.6%)
Elevated serum creatinine 9 (20.5%)
Elevated PCT levels 26 (59.1%)
Elevated CRP levels 26 (59.1%)
Radiological examinations
Bilateral involvement 34 (77.3%)
Unilateral involvement 4 (9.1%)
Management
Only antimicrobial treatment 29 (65.9%)
Antimicrobial and surgical thrapy 14 (31.8%)
Outcome
Cured or improved 36 (81.8%)
Unilateral involvement 4 (9.1%)
Management
Only antimicrobial treatment 29 (65.9%)
Antimicrobial and surgical thrapy 14 (31.8%)
Outcome
Cured or improved 36 (81.8%)
Poor prognosis 5 (11.4%)
Lost follow-up 2 (4.5%)
Died 1 (2.3%)

Abbreviations: CTD: Connective Tissue disease; CHD: Coronary heart disease; CNS: central nervous system

Of the 44 patients, 36 had underlying diseases. The most common condition was CTD (16/44), followed by chronic kidney disease (10/44), hypertension (9/44), and diabetes (7/44) (Table 1). Nineteen patients had two or more underlying diseases.

Twenty-six patients (59.1%) were previously treated with glucocorticoids or immunosuppressive therapy, including intravenously administered methylprednisolone and oral prednisolone.

Clinical Characteristic of Nocardiosis Patients

Seventeen patients (38.6%) only had pulmonary nocardiosis. Involvement of skin and soft tissue was found in 8 patients (18.2%), while the CNS was involved in 6 patients (13.6%), and 1 patient (2.3%) presented with an eye infection. Twelve patients (27.3%) presented with disseminated nocardiosis, including 6 patients with bloodstream infection, 4 patients with lung, skin, and soft tissue infection, and 2 patients with lung and intraperitoneal infections. The distribution of infection sites is shown in Fig. 2.

Fig. 2. The distribution of infection sites.

Fig. 2

The most frequent infection sites were the lungs and skin and soft tissue. Twelve patients (27.3%) presented disseminated nocardiosis.

The clinical manifestations varied widely. Cough was noted in 23 patients (52.3%), expectoration in 18 patients (40.9%), fever in 15 patients (34.1%), subcutaneous abscesses in 15 patients (34.1%), shortness of breath in 10 patients (22.7%), headache in 7 patients (15.9%), muscle soreness in 6 patients (13.6%), asthenia in 6 patients (13.6%), and altered consciousness and hemoptysis in 4 patients each (10.3%) (Table 1).

Isolates and Nocardia species Identification

Nocardia strains were isolated from 54 specimens, including sputum or bronchial secretions (n =16), bronchoalveolar lavage (n = 6), skin abscesses or abscess puncture fluid (n = 11), wound secretions or pus (n =7), blood (n = 6), CSF or brain abscess drainage (n =3), and others (n = 4). The average time taken for microbial detection was 4.8 days. Forty-five specimens exceeded the conventional culture time (>2 days) and prolonged the culture time. Twenty of these were found a Gram-positive, filamentous, or partially acid-fast branched bacterium suspected to be Nocardia from smear microscopic examination (Gram staining and modified acid-fast staining), so the microbiologists decided to extend their culture time. Twenty-four specimens required more than 4.8 days, and 11 specimens required more than 7 days.

Among the 44 Nocardia isolates, only 30 were identified beyond the genus level. The most common species isolated were N. farcinica (n = 9, 20.5%), N. cyricigeorgica (n = 8, 18.2%), N. brasilliensis (n = 3, 6.8%), N. asterioes (n =2, 4.6%), N. abscessus (n =2, 4.6%), N. nova (n = 2, 4.6%), N. araoensis (n =2, 4.6%), N. otitidiscaviarum (n=1, 2.3%), and N. pseudobrasiliensis (n = 1, 2.3%). Fourteen isolates (n = 14, 31.8%) could not be identified at the species level (Fig. 3).

Fig. 3. Distribution of Nocardia spp.

Fig. 3

Among the 44 Nocardia isolates, only 30 were identified beyond the genus level. The most common species isolated were N. farcinica (n = 9, 20.5%), N. cyricigeorgica (n = 8, 18.2%), N. brasilliensis (n = 3, 6.8%), N. asterioes (n = 2, 4.6%), N. abscessus (n = 2, 4.6%), N. nova (n = 2, 4.6%), N. araoensis (n = 2, 4.6%), N. otitidiscaviarum (n = 1, 2.3%), N. pseudobrasiliensis (n = 1, 2.3%), and 14 isolates could not be identified at the species level.

Laboratory Tests and Radiological Examinations

Of the 44 patients, 26 patients (59.1%) showed elevated white cells, 30 patients (68.2%) showed elevated neutrophil proportion, and 34 patients (77.3%) showed decreased lymphocyte counts. Serum CRP levels were elevated in 26 patients (59.1%), and PCT levels were increased in 26 patients (59.1%). Twenty patients (45.5%) showed lower hemoglobin levels, and 7 patients (15.9%) showed elevated platelet counts. The level of serum album decreased in 32 patients (72.7%), 28 patients (63.6%) presented with an elevated ECR, and 9 patients (20.5%) had elevated serum creatinine levels(Table 1).

Bilateral involvement was detected in the chest CT images of 34 patients (77.3%), while 4 patients (9.1%) had unilateral involvement. All pulmonary nocardiosis cases showed abnormal chest CT findings. The most common radiological findings were nodules (38.6%), pleural effusion (15.9%), and patchy shadows (15.9%). Other imaging findings, such as cavities (11.4%), stripe-shape (11.4%), and mediastinal lymph node enlargement (9.1%) were relatively rare. Among the 6 CNS infection cases, 5 patients had intracranial space-occupying lesions, and 1 patient showed cerebral atrophy in magnetic resonance imaging.

Management and Outcome

Twenty-nine patients were managed using only antimicrobial treatment, and 14 patients received both antimicrobial and surgical therapies. One patient had unclear medication.

Approximately 47.7% of patients received empirical antimicrobial therapy before the culture results were available, but they were rarely successful in those cases and clinicians usually changed the medication and eventually prescribed trimethoprim-sulfamethoxazole (TMP-SMX). Three patients (6.8%) were treated with TMP-SMX alone, and 28 patients (63.6%) had received other antibiotics in combination. The antimicrobial agents included oxazolidinones (linezolid), carbapenems (imipenem and meropenem), quinolones (moxifloxacin and levofloxacin), cephalosporins (ceftriaxone and cefoperazone-sulbactam), and aminoglycosides (amikacin). The remaining 12 patients were administered one or more antibiotics other than TMP-SMX.

Thirty-six patients were cured or improved, 5 were discharged from the hospital due to serious illness or poor prognosis, 2 outpatients were lost to follow-up, and 1 patient died. In addition, 2 patients experienced relapse, 1 of whom was cured, while the other patient died. In cases with poor prognosis (6 patients), all patients had underlying diseases, 5 patients used immunosuppressants, and 4 of which had CTDs. Moreover, 5 had received empirical antimicrobial therapy before the culture results were available.

The average diagnosis time of cases with poor prognosis was 19.7 days, while that of improved or cured patients was only 7.3 days. There was no difference in the average therapy duration between patients who had been cured/improved or had poor prognoses. The specific times for diagnosis, therapy, and disease duration are shown in Supplementary Material.

Discussion

This is one of the largest contemporary single-center retrospective studies to describe the clinical characteristics and management of 44 patients with nocardiosis in China, to date. Nocardiosis mainly occurs in middle-aged and elderly men, and is frequently complicated by a series of underlying diseases [8, 20, 21]. Unlike other studies that reported chronic lung diseases as the most common underlying diseases, our findings suggest that immunocompromised patients, especially those with CTDs, can be vulnerable to nocardiosis [17, 22]. CTD patients on either glucocorticoids or immunosuppressive drugs were the most common nocardiosis cases at our institution, and the infection sites were predominantly in the lungs and skin. Consistently, a retrospective study from Israel showed that immunosuppressive drug therapy was positively correlated with nocardiosis [23].

Isolation and culture are the principal methods for diagnosis of nocardiosis, and longer culture time and smear microscopic examination improves detection sensitivity [24]. At present, isolation of Nocardia on common or selective media usually takes 2-7 days and some strains even need 2-4 weeks to generate available results, causing a delay in diagnosis[13, 16, 17, 25-27] . In our study, most specimens required extended culture time (>2 days). Hence, to avoid missing detection and increase the detection rates, clinicians should inform microbiologists of suspicious cases and require that more attention be paid to these specimens. Microbiologists should also consider prolonging the culture time and continue observation via the smear microscopic examination (Gram staining and modified acid-fast staining) on the other. A previous study of confirmed nocardiosis patients also demonstrated that Gram staining was a sensitive method for recognizing Nocardia in clinical specimens [28].

The distribution of Nocardia showed observable geographical variations. In our study, ten Nocardia species were identified among the 44 isolates. N. farcinica was the most common species, followed by N. cyricigeorgica and N.brasilliensis, which agreed with a recent study in China [15]. In other case series, the most frequently isolated Nocardia were diverse, including N. cyricigeorgica in Australia [17] and Japan [29], N. brasiliensis in Taiwan [18], and N. nova in the United States [30]. Moreover, a French retrospective analysis suggested that distributions may change over time, which has been reported for the increasing N. farcinica proportion from 2010 (13%) to 2014 (27.6%) [31]. Therefore, it’s meaningful to monitor the temporal and spatial changes in Nocardia distribution.

Clinical symptoms, radiological findings and inflammatory parameters (including leukocytes, neutrophils, CRP, and PCT) play an important role in the diagnosis of nocardiosis but lack specificity [28, 32]. In this study, the lungs and skin were the most common infection sites. Respiratory symptoms, detailed skin examination, and chest CT could be beneficial to clinicians in identifying the infection sites [8]. CNS infection could present with brain abscesses, and the frontal and parietal regions were commonly affected.

Empirical antimicrobial treatments before definite diagnosis do not work for all nocardiosis cases, and appropriate and personalized treatment after bacterial culture is recommended. In our study, approximately half of the cases recieved empirical antimicrobial therapy before the culture results were available, but they were rarely successful, and clinicians usually changed the medication and eventually prescribed TMP-SMX.

TMP-SMX is the drug of first choice for nocardiosis, and most Nocardia spp. are susceptible to it [29, 33]. For TMP-SMX-resistant, disseminated, or severe nocardiosis, a combination of TMP-SMX with other antibiotics is recommended [28]. Currently increased resistance towards TMP-SMX has been observed. One retrospective evaluation study in the USA from 1995 to 2004 showed a TMP-SMX resistance rate of 42% [30]. Another report from Spain in 2011 found that 16.1% cases were resistance to TMP-SMX [34]. Therefore, according to the Sanford Guide to Antimicrobial Therapy 2018 [35], TMP-SMX with imipenem or amikacin should be considered in disseminated nocardiosis patients. Linezolid is also an appealing alternative, because it has high bioavailability and most Nocardia show susceptibility [36]. Other alternative treatment options include minocycline, amikacin, and meropenem [19]. In terms of treatment, 3 months is recommended for immunocompetent patients, at least 6 months for immune-compromised patients, and at least a year for patients with CNS involvement [7]. It has been reported that longer therapy duration may be preferable to prevent recurrence [37]. In our study, nocardiosis management generally agreed with was the above therapies and most patients cured.

Earlier diagnosis and administration are beneficial for the prognosis, so clinicians’ awareness of nocardiosis should be improved to accelerate the process of diagnosis [33]. In cases with poor prognosis (6 patients), the clinicians did not suspect that the patients’ abnormal clinical characteristics were caused by Nocardia in the early stage. The average diagnosis time for patients with poor prognoses were much longer than those for the cured or improved patients, which caused delays in treatment of patients, likely led to initial noneffective empirical treatments and affected the prognosis.

Our study had some limitations. First, it was a single-center study, and the clinical characteristics are regional-limited; multi-center studies would improve the reliability of the data. Moreover, the sample size is small, thus a larger sample size and additional research data are needed to further support these conclusions. Second, as this was a retrospective study, some information, such as outpatient history, was incomplete. Third, we only used the MALDI-TOF-MS to identify the Nocardia isolates, and they were not verified by purified PCR product and sequencing the full length of the 16S RNA gene. Also, antimicrobial susceptibility tests were not performed in this study.

In conclusion, earlier diagnosis and administration are beneficial for improving the prognosis of nocardiosis. Attention should be paid to immunocompromised patients and nocardiosis should be considered. Prolonged cultivation time helps with nocardia detection. Improving diagnostic efficiency at early stage is of particular importance to achieve favorable prognosis in nocardiosis.

Supplemental Materials

jmb-33-5-574-supple.pdf (334.2KB, pdf)

Supplementary data for this paper are available on-line only at http://jmb.or.kr.

Acknowledgments

We thank all the staff in the Microbiology Department of Xiangya Hospital for their kind help. This work was supported by the National Natural Science Foundation of China (grant number 81672066).

Footnotes

Authors Contributions

Proposed and directed the study: WL, XL; Data collection: PL, ZW, ZJ and YL; Prepared the first draft: PL; Revised the manuscript: WL, PL, ZW, XL, QY, BZ, ML. All authors read and approved the final draft of the manuscript.

Ethical Approval and Informed Consent

This research was carried out in compliance with the recommendations of the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Central South University Ethics Committee (Changsha, Hunan Province, People’s Republic of China) with ID 202112273.

Conflict of Interest

The authors have no financial conflicts of interest to declare.

References

  • 1.Nakamura I, Nagakura T, Fujita H, Fukusima S, Gonoi T. Nocardia elegans infection: a case report and literature review. Int. J. Infect. Dis. 2017;54:15–17. doi: 10.1016/j.ijid.2016.10.031. [DOI] [PubMed] [Google Scholar]
  • 2.Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin. Proc. 2012;87:403–407. doi: 10.1016/j.mayocp.2011.11.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Martinez R, Reyes S, Menendez R. Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. Curr. Opin. Pulm. Med. 2008;14:219–227. doi: 10.1097/MCP.0b013e3282f85dd3. [DOI] [PubMed] [Google Scholar]
  • 4.Conville PS, Brown-Elliott BA, Smith T, Zelazny AM. The complexities of nocardia taxonomy and identification. J. Clin. Microbiol. 2018;56:e01419–17. doi: 10.1128/JCM.01419-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Minero MV, Marin M, Cercenado E, Rabadan PM, Bouza E, Munoz P. Nocardiosis at the turn of the century. Medicine (Baltimore) 2009;88:250–261. doi: 10.1097/MD.0b013e3181afa1c8. [DOI] [PubMed] [Google Scholar]
  • 6.Carrasco G, Valdezate S, Garrido N, Villalon P, Medina-Pascual MJ, Saez-Nieto JA. Identification, typing, and phylogenetic relationships of the main clinical Nocardia species in spain according to their gyrB and rpoB genes. J. Clin. Microbiol. 2013;51:3602–3608. doi: 10.1128/JCM.00515-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Jiang Y, Huang A, Fang Q. Disseminated nocardiosis caused by Nocardia otitidiscaviarum in an immunocompetent host: a case report and literature review. Exp. Ther. Med. 2016;12:3339–3346. doi: 10.3892/etm.2016.3755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Corsini Campioli C, Castillo Almeida NE, O'Horo JC, Challener D, Go JR, DeSimone DC, et al. Clinical presentation, management, and outcomes of patients with brain abscess due to Nocardia species. Open Forum Infect. Dis. 2021;8:ofab067. doi: 10.1093/ofid/ofab067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lynch JP, 3rd, Reid G, Clark NM. Nocardia spp. a rare cause of pneumonia globally. Semin. Respir. Crit. Care Med. 2020;41:538–554. doi: 10.1055/s-0040-1708816. [DOI] [PubMed] [Google Scholar]
  • 10.Mehta HH, Shamoo Y. Pathogenic Nocardia: a diverse genus of emerging pathogens or just poorly recognized? PLoS Pathog. 2020;16:e1008280. doi: 10.1371/journal.ppat.1008280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wintheiser GA, Venable ER, Temesgen Z. Disseminated Nocardia in an immunocompetent host. Mayo Clin. Proc. 2021;96:847–848. doi: 10.1016/j.mayocp.2020.11.019. [DOI] [PubMed] [Google Scholar]
  • 12.Coussement J, Lebeaux D, van Delden C, Guillot H, Freund R, Marbus S, et al. Nocardia infection in solid organ transplant recipients: A multicenter European case-control study. Clin. Infect. Dis. 2016;63:338–345. doi: 10.1093/cid/ciw241. [DOI] [PubMed] [Google Scholar]
  • 13.Weng SS, Zhang HY, Ai JW, Gao Y, Liu YY, Xu B, et al. Rapid detection of Nocardia by next-generation sequencing. Front. Cell. Infect. Microbiol. 2020;10:13. doi: 10.3389/fcimb.2020.00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Agterof MJ, van der Bruggen T, Tersmette M, ter Borg EJ, van den Bosch JM, Biesma DH. Nocardiosis: a case series and a mini review of clinical and microbiological features. Neth. J. Med. 2007;65:199–202. [PubMed] [Google Scholar]
  • 15.Wang H, Zhu Y, Cui Q, Wu W, Li G, Chen D, et al. Epidemiology and antimicrobial resistance profiles of the Nocardia species in China, 2009 to 2021. Microbiol. Spectr. 2022;10:e0156021. doi: 10.1128/spectrum.01560-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ., Jr Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin. Microbiol. Rev. 2006;19:259–282. doi: 10.1128/CMR.19.2.259-282.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Paige EK, Spelman D. Nocardiosis: 7-year experience at an Australian tertiary hospital. Intern. Med. J. 2019;49:373–379. doi: 10.1111/imj.14068. [DOI] [PubMed] [Google Scholar]
  • 18.Liu WL, Lai CC, Ko WC, Chen YH, Tang HJ, Huang YL, et al. Clinical and microbiological characteristics of infections caused by various Nocardia species in Taiwan: a multicenter study from 1998 to 2010. Eur. J. Clin. Microbiol. Infect. Dis. 2011;30:1341–1347. doi: 10.1007/s10096-011-1227-9. [DOI] [PubMed] [Google Scholar]
  • 19.Margalit I, Lebeaux D, Tishler O, Goldberg E, Bishara J, Yahav D, et al. How do I manage nocardiosis? Clin. Microbiol. Infect. 2021;27:550–558. doi: 10.1016/j.cmi.2020.12.019. [DOI] [PubMed] [Google Scholar]
  • 20.Huang L, Chen X, Xu H, Sun L, Li C, Guo W, et al. Clinical features, identification, antimicrobial resistance patterns of Nocardia species in China: 2009-2017. Diagn. Microbiol. Infect. Dis. 2019;94:165–172. doi: 10.1016/j.diagmicrobio.2018.12.007. [DOI] [PubMed] [Google Scholar]
  • 21.Mari B, Monton C, Mariscal D, Lujan M, Sala M, Domingo C. Pulmonary nocardiosis: clinical experience in ten cases. Respiration. 2001;68:382–388. doi: 10.1159/000050531. [DOI] [PubMed] [Google Scholar]
  • 22.Kudru CU, Kumar A, Chawla K, Minnamreddigari C, Siddalingaiah N, Guddattu V. A ten-year retrospective analysis of nocardiosis in a tertiary care center of South-coastal India. Infez. Med. 2021;29:600–608. doi: 10.53854/liim-2904-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Margalit I, Goldberg E, Ben Ari Y, Ben-Zvi H, Shostak Y, Krause I, et al. Clinical correlates of nocardiosis. Sci. Rep. 2020;10:14272. doi: 10.1038/s41598-020-71214-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Fatahi-Bafghi M. Nocardiosis from 1888 to 2017. Microb. Pathog. 2018;114:369–384. doi: 10.1016/j.micpath.2017.11.012. [DOI] [PubMed] [Google Scholar]
  • 25.Wang A, Xu Q, Wang Y, Liao H. Orbital and intracranial Nocardia farcinica infection caused by trauma to the orbit: a case report. BMC Infect. Dis. 2019;19:953. doi: 10.1186/s12879-019-4605-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sawai T, Nakao T, Yamaguchi S, Yoshioka S, Matsuo N, Suyama N, et al. Detection of high serum levels of beta-D-Glucan in disseminated nocardial infection: a case report. BMC Infect. Dis. 2017;17:272. doi: 10.1186/s12879-017-2370-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jiao M, Deng X, Yang H, Dong J, Lv J, Li F. Case report: a severe and multi-Site Nocardia farcinica infection rapidly and precisely identified by metagenomic next-generation sequencing. Front. Med. (Lausanne) 2021;8:669552. doi: 10.3389/fmed.2021.669552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J. Clin. Microbiol. 2003;41:4497–4501. doi: 10.1128/JCM.41.10.4497-4501.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Toyokawa M, Ohana N, Ueda A, Imai M, Tanno D, Honda M, et al. Identification and antimicrobial susceptibility profiles of Nocardia species clinically isolated in Japan. Sci. Rep. 2021;11:16742. doi: 10.1038/s41598-021-95870-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Uhde KB, Pathak S, McCullum I, Jr, Jannat-Khah DP, Shadomy SV, Dykewicz CA, et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin. Infect. Dis. 2010;51:1445–1448. doi: 10.1086/657399. [DOI] [PubMed] [Google Scholar]
  • 31.Lebeaux D, Bergeron E, Berthet J, Djadi-Prat J, Mouniee D, Boiron P, et al. Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010-2015. Clin. Microbiol. Infect. 2019;25:489–495. doi: 10.1016/j.cmi.2018.06.013. [DOI] [PubMed] [Google Scholar]
  • 32.Sah R, Khadka S, Neupane S, Nepal G, Singla S, Kumari P, et al. Disseminated infection with Nocardia otitidiscaviarum in a patient under steroid therapy. Clin. Case Rep. 2020;8:369–373. doi: 10.1002/ccr3.2640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Yagishita M, Tsuboi H, Tabuchi D, Sugita T, Nishiyama T, Okamoto S, et al. Clinical features and prognosis of nocardiosis in patients with connective tissue diseases. Mod. Rheumatol. 2021;31:636–642. doi: 10.1080/14397595.2020.1823070. [DOI] [PubMed] [Google Scholar]
  • 34.Larruskain J, Idigoras P, Marimon JM, Perez-Trallero E. Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents. Antimicrob. Agents Chemother. 2011;55:2995–2998. doi: 10.1128/AAC.01279-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Pavia AT. The Sanford guide to antimicrobial therapy, pp. 7. Ed. 2018. [Google Scholar]
  • 36.Tremblay J, Thibert L, Alarie I, Valiquette L, Pepin J. Nocardiosis in Quebec, Canada, 1988-2008. Clin. Microbiol. Infect. 2011;17:690–696. doi: 10.1111/j.1469-0691.2010.03306.x. [DOI] [PubMed] [Google Scholar]
  • 37.Xu H, Fu B, Xu L, Sun J. Disseminated Nocardiosis with subretinal abscess in a patient with nephrotic syndrome-a case report. BMC Ophthalmol. 2018;18:234. doi: 10.1186/s12886-018-0883-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

jmb-33-5-574-supple.pdf (334.2KB, pdf)

Supplementary data for this paper are available on-line only at http://jmb.or.kr.


Articles from Journal of Microbiology and Biotechnology are provided here courtesy of Korean Society for Microbiology and Biotechnology

RESOURCES